References
- Zaki I, Fitzgerald P, Hardy J, Wilson C. A comparison of the effect of viscosity on the precorneal residence of solutions in rabbit and man. Journal of pharmacy and pharmacology. 1986;38(6):463-6.10.1111/j.2042-7158.1986.tb04611.x2873224
- Lee VH, Robinson, R J. Topical ocular drug delivery: recent developments and future challenges. Journal of ocular pharmacology and therapeutics. 1986;2(1):67-108.10.1089/jop.1986.2.673332284
- Karthikeyan D, Bhowmick M, Pandey VP, Nandhakumar J, Sengottuvelu S, Sonkar S, et al. The concept of ocular inserts as drug delivery systems: An overview. Asian Journal of Pharmaceutics. 2014;2(4):192-200.10.4103/0973-8398.45031
- Friedrich SW, Saville BA, Cheng Y-L, Rootman DS. Pharmacokinetic differences between ocular inserts and eyedrops. Journal of ocular pharmacology and therapeutics. 1996;12(1):5-18.10.1089/jop.1996.12.58925396
- Schoenwald R. Ocular pharmacokinetics/pharmacodynamics. Drug and the pharmaceutical sciences. 1993;58:83-110.
- Kumar KS, Bhowmik D, Harish G, Duraivel SJ. Ocular inserts: A novel controlled drug delivery system. The Pharma Innovation Journal. 2013;1(12, Part A):1-16.
- Cervantes LJ, Mah FS. Clinical use of gatifloxacin ophthalmic solution for treatment of bacterial conjunctivitis. Clinical ophthalmology (Auckland, NZ). 2011;5:495-502.
- Mohd Abul K, Aws A, Ibrahim AA, Anil KM, Yasmin S. Delivery of gatifloxacin using microemulsion as vehicle: formulation, evaluation, transcorneal permeation and aqueous humor drug determination. Drug Delivery. 2014;23(3):886-97.
- Pawar P, Katara R, Mishra S, Majumdar DK. Topical ocular delivery of fluoroquinolones. Expert opinion on drug delivery. 2013;10(5):691-711.10.1517/17425247.2013.77297723419018
- Perry CM, Balfour JAB, Lamb HM. Gatifloxacin. Drugs. 1999;58(4):683-96.10.2165/00003495-199958040-0001010551438
- Indian Pharmacopoeia. Government of India, ministry of health and family welfare. Delhi: Controller of Publications. 2010:1402,951.
- Laurell CG, Zetterström C. Effects of dexamethasone, diclofenac, or placebo on the inflammatory response after cataract surgery. Br J Ophthalmol. 2002;86(12):1380-4.10.1136/bjo.86.12.1380177143912446370
- Barnes PJ. How corticosteroids control inflammation: Quintiles Prize Lecture 2005. Br J Pharmacol. 2006;148(3):245-54.10.1038/sj.bjp.0706736175155916604091
- Ilyas H, Slonim CB, Braswell GR, Favetta JR, Schulman M. Long-term safety of loteprednol etabonate 0.2% in the treatment of seasonal and perennial allergic conjunctivitis. Eye contact lens. 2004;30(1):10-3.10.1097/01.ICL.0000092071.82938.4614722462
- Campos M, Muccioli C, Malta JB, Gerade RA, A LAS, Belfort R. Efficacy and tolerability of a combined gatifloxacin plus prednisolone formulation for topical prophylaxis after LASIK. Clinical ophthalmology (Auckland, NZ). 2011;5:209-14.
- Awan MA, Agarwal PK, Watson DG, McGhee CN, Dutton GN. Penetration of topical and subconjunctival corticosteroids into human aqueous humour and its therapeutic significance. Br J Ophthalmol. 2009;93(6):708-13.10.1136/bjo.2008.15490619293163
- Kiningham KK. Prednisolone. xPharm: The Comprehensive Pharmacology Reference. 2007:1-6.10.1016/B978-008055232-3.62454-7
- Cunha PA, Shinzato FA, Tecchio GT, Weber SL, Brasil A, Avakian A. Efficacy and tolerability of a gatifloxacin/prednisolone acetate fixed combination for topical prophylaxis and control of inflammation in phacoemulsification: a 20-day-double-blind comparison to its individual components. Clinics (Sao Paulo, Brazil). 2013;68(6):834-9.10.6061/clinics/2013(06)18
- Ayaki M, Taguchi Y, Soda M, Yaguchi S, Iwasawa A, Koide R. Cytotoxicity of topical medications used for infection and inflammation control after cataract surgery in cultured corneal endothelial cells. Biocontrol science. 2010;15(3):97-102.10.4265/bio.15.9720938094
- Ayaki M, Yaguchi S, Iwasawa A, Koide R. Cytotoxicity of ophthalmic solutions with and without preservatives to human corneal endothelial cells, epithelial cells and conjunctival epithelial cells. Clinical & experimental ophthalmology. 2008;36(6):553-9.10.1111/j.1442-9071.2008.01803.x18954319
- Banu S, Farheen SA. Ocular Drug Delivery System: A Novel Approach. Asian Journal of Research in Pharmaceutical Science. 2019;9(2):97-106.10.5958/2231-5659.2019.00015.8
- Kumari A, Sharma P, Garg V, Garg G. Ocular inserts - Advancement in therapy of eye diseases. J Adv Pharm Technol Res. 2010;1(3):291-6.10.4103/0110-5558.72419325540722247860
- Rajesh A, Poonam D, Sangeeta A. Ocular drug delivery system: ocular insert. International Journal of Universal Pharmacy and Bio Sciences. 2012;1(2):30-8.
- Kumari A, Sharma PK, Garg VK, Garg G. Ocular inserts - Advancement in therapy of eye diseases. J Adv Pharm Technol Res. 2010;1(3):291-6.10.4103/0110-5558.72419
- Ghosh S, Barik B. Formulation and in vitro evaluation of once daily sustained release formulation of aceclofenac. Tropical journal of pharmaceutical research. 2010;9(3):265-73.10.4314/tjpr.v9i3.56288
- Freire F, Aragão C, de Lima e Moura T, Raffin F. Compatibility study between chlorpropamide and excipients in their physical mixtures. Journal of thermal analysis calorimetry. 2009;97(1):355-7.10.1007/s10973-009-0258-2
- Renu C, Swati B. Drug–excipient compatibility screening—Role of thermoanalytical and spectroscopic techniques. Journal of Pharmaceutical and Biomedical Analysis. 2014;87:82-97.10.1016/j.jpba.2013.06.01623845418
- Oliveira G, Ferraz H, Matos J. Thermoanalytical study of glibenclamide and excipients. Journal of thermal analysis calorimetry. 2005;79(2):267-70.10.1007/s10973-005-0047-5
- Ibrahim HK, El-Leithy IS, Makky AA. Mucoadhesive Nanoparticles as Carrier Systems for Prolonged Ocular Delivery of Gatifloxacin/Prednisolone Bitherapy. Molecular Pharmaceutics. 2010;7(2):576-85.10.1021/mp900279c20163167
- Tanwar Y, Patel D, Sisodia S. In vitro and in vivo evaluation of ocular inserts of ofloxacin. DARU. 2007:139-45.
- Karthikeyan D, Bhowmick M, Pandey V, Sengottuvelu S, Sonkar S, Gupta N, et al. Design and evaluation of ofloxacin extended release ocular inserts for once a day therapy. Res J Pharm Tech. 2008;1(4):460-8.
- Kalyanwat R, Shrivastava B, Pathak K. Preparation and Evaluation of bioadhesive ocular inserts of aceclofenac. International Journal of Pharmaceutical Sciences Review and Research. 2016;41:207-13.
- Saroot R, Gilhotra RM. Design and characterization of bioadhesive ophthalmic films of flurbiprofen. Thai Journal of Pharmaceutical Science. 2011;35:29-39.
- Pawar S, Pawar R, Gadhve M. Controlled release in situ forming gatifloxacine HCl for ophthalmic drug delivery. Int Res J of Phar. 2012;3:86-9.
- Patel UL, Chotai NP, Nagda CD. Design and evaluation of ocular drug delivery system for controlled delivery of gatifloxacin sesquehydrate: In vitro and in vivo evaluation. Pharmaceutical development technology. 2012;17(1):15-22.10.3109/10837450.2010.50217820649410
- Mathurm M, Gilhotra RM. Glycerogelatin-based ocular inserts of aceclofenac: physicochemical, drug release studies and efficacy against prostaglandin E2-induced ocular inflammation. Drug delivery. 2011;18(1):54-64.10.3109/10717544.2010.50936620718601
- Charoo NA, Kohli K, Ali A, Anwer A. Ophthalmic delivery of ciprofloxacin hydrochloride from different polymer formulations: in vitro and in vivo studies. Drug development industrial pharmacy. 2003;29(2):215-21.10.1081/DDC-120016729
- Chandran S, Roy A, Saha RN. Effect of pH and formulation variables on in vitro transcorneal permeability of flurbiprofen: a technical note. Aaps Pharmscitech. 2008;9(3):1031-7.10.1208/s12249-008-9139-4297702518792792
- Dash S, Murthy PN, Nath L, Chowdhury P. Kinetic modeling on drug release from controlled drug delivery systems. Acta Pol Pharm. 2010;67(3):217-23.
- Indian Pharmacopoeia. Government of India, ministry of health and family welfare. Delhi: Controller of Publications. 1996;2(35):448-89, A-147.
- ICH harmonized tripartite guideline. Stability testing of new drug substances andproducts Q1A (R2).1-18.